Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 414.76% […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 414.76% […]
